Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life

This registered clinical trial, not yet recruiting as of mid-2025, asks whether giving probiotics to infants who were exposed to antibiotics early in life — either before birth or in the first weeks after — can reduce their chances of developing allergic diseases such as eczema, asthma, or food allergy. The background reasoning is straightforward: antibiotics disrupt the normal colonization of the infant gut by wiping out beneficial bacteria, and that disruption (dysbiosis) is increasingly linked in epidemiological studies to a higher lifetime risk of allergy. Probiotics are live bacteria that may help restore microbial balance, strengthen the gut lining, and re-tune the immune system toward a less allergy-prone state — for example, by shifting the Th1/Th2 ratio, expanding regulatory T cells, and boosting secretory IgA. Most existing probiotic-allergy trials have enrolled general or broadly 'high-risk' infant populations; this trial deliberately targets the narrower, arguably higher-risk subgroup of infants who have already received antibiotics. Because no high-quality randomized controlled trial has yet filled this specific evidence gap, the study is designed as an RCT to produce the rigorous causal evidence that observational data cannot provide. If the intervention proves effective, it could translate into a simple, low-cost add-on to antibiotic prescribing practice in neonatal and early-infant care. The results would also help clarify which biological mechanisms most plausibly link early dysbiosis to allergic sensitization.

• No efficacy or safety results are available — the trial is in the pre-recruitment planning phase (status: NOT_YET_RECRUITING; anticipated start 2026-05-11).
• The study rationale synthesizes epidemiological evidence that both prenatal and postnatal antibiotic exposure are significantly associated with increased childhood allergic disease risk, justifying the targeted enrollment strategy.
• Proposed mechanistic endpoints include markers of Th1/Th2 immune balance, regulatory T-cell induction, and secretory IgA (sIgA) secretion — reflecting the three dominant immunological pathways through which probiotics are hypothesized to confer protection.

This is a prospective randomized controlled trial (RCT) registered at ClinicalTrials.gov (NCT07532421) and sponsored by Peking University Third Hospital. The target population is infants who have been exposed to antibiotics during the prenatal or early postnatal period, representing a defined high-risk subgroup. Specific sample size, probiotic strain(s), dosing regimen, randomization ratio, and planned follow-up duration are not yet disclosed in the registered abstract. Outcome measures are expected to include incidence of allergic diseases (e.g., atopic dermatitis, wheeze, food allergy) and mechanistic immunological parameters, based on the stated study rationale.

Because the trial has not yet begun recruiting, no data on feasibility, retention, or effect size are available, and all methodological details (strain selection, dose, duration, blinding procedures, primary endpoint definition) remain unverified from the public registration record alone — confidence in methods description is therefore low. The focus on a single high-risk subgroup (antibiotic-exposed infants) improves internal validity but will limit generalizability to infants without antibiotic exposure. Antibiotic type, timing, and cumulative dose are heterogeneous exposures that may confound within-trial comparisons if not carefully stratified. The next clarifying experiment would be a dose-finding or strain-comparison sub-study to determine which probiotic formulation produces the largest and most durable immunological shift in this specific dysbiotic context.

This trial extends [§150], which provides the foundational mechanistic framework linking gut microbiota composition to immune-mediated inflammatory disease, by applying that framework to a concrete preventive intervention in a vulnerable neonatal population. It also parallels [§151], which examines immunomodulatory effects of Bifidobacterium bifidum in a chemically immunosuppressed model, offering pre-clinical mechanistic evidence for the probiotic-immune axis that this RCT seeks to validate clinically. The intestinal barrier stabilization rationale invoked in the trial design is directly contextualized by [§155], a study on Saccharomyces boulardii's effects on intestinal barrier function, illustrating the shared mechanistic logic across probiotic species. More broadly, the trial parallels [§144], which surveys molecular pathways and clinical applications of probiotics across gut, neurologic, and cardiometabolic domains, situating allergy prevention as one node in a wider probiotic-efficacy landscape. Together these articles confirm that the mechanistic pillars this trial rests on — barrier integrity, Th1/Th2 rebalancing, regulatory T-cell induction — are active research priorities across the corpus, though high-quality RCT evidence in antibiotic-exposed infants specifically remains the gap this study is designed to close.

• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Directly examines how a probiotic organism (Saccharomyces boulardii) modulates intestinal barrier function — the same mechanistic endpoint invoked as a key rationale for probiotic use in this antibiotic-exposed infant trial.
• Immunomodulatory Effects of Bifidobacterium bifidum BGN4 in Cyclophosphamide-induced Immunosuppressed Mice via Activation of NK Cells and Macrophages
  Provides experimental evidence that Bifidobacterium bifidum reshapes immune responses (NF-κB pathway, cytokine profiles) in an immunocompromised host, offering a pre-clinical parallel to the immunomodulatory claims underpinning this RCT.
• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  An editorial synthesizing the gut microbiota–immune inflammatory disease axis that serves as the conceptual backbone of this trial; reading it alongside the trial registration reveals which mechanistic links still lack RCT-level support.
• Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review
  Broad review of probiotic molecular pathways and clinical applications across disease areas; comparing it with this narrowly targeted RCT highlights the evidence gap between general probiotic science and population-specific intervention trials.
• Multi-omics Analysis Reveals the Protection of a Quadruple Probiotic Mixture in Experimental Autoimmune Hepatitis
  Uses multi-omics to characterize how a quadruple probiotic mixture modulates immune and microbial pathways in an autoimmune model, providing methodological and mechanistic context for interpreting multi-strain versus single-strain probiotic strategies relevant to this trial's design choices.